# EDGAR Filing Document

**Accession Number:** 0001785971
**File Stem:** 0001410368-26-054486
**Filing Date:** 2026-5
**Character Count:** 97257
**Document Hash:** 1bafa27e00319f0548c84832fe42fd4c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001410368-26-054486.hdr.sgml**: 20260528

**ACCESSION NUMBER**: 0001410368-26-054486

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260528

**DATE AS OF CHANGE**: 20260528

**PERIOD START**: 20261231

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BlackRock Health Sciences Term Trust
- **CENTRAL INDEX KEY:** 0001785971

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-23466
- **FILM NUMBER:** 261030887

**BUSINESS ADDRESS:**
- **STREET 1:** 100 BELLEVUE PARKWAY
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19809
- **BUSINESS PHONE:** 800 882 0052

**MAIL ADDRESS:**
- **STREET 1:** 100 BELLEVUE PARKWAY
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19809

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BlackRock Health Sciences Trust II
- **DATE OF NAME CHANGE:** 20190820

## Nport-Ex

March 31, 2026

2026 Quarterly Report <br>&nbsp;&nbsp;&nbsp;&nbsp;(Unaudited)<br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**BlackRock Health Sciences Term Trust (BMEZ)**<br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**Not FDIC Insured • May Lose Value • No Bank Guarantee**<br>

------

Schedule of Investments (unaudited)

March 31, 2026

**BlackRock Health Sciences Term Trust (BMEZ)** 

**(Percentages shown are based on Net Assets)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | |
|:---|:---|:---|
| *Security* | <br>*Shares*<br>| *Value* |
| **Common Stocks** | **Common Stocks** | **Common Stocks** |
| **Biotechnology — 37.0%** | **Biotechnology — 37.0%** |  |
| 4D Molecular Therapeutics, Inc.<sup>(a)</sup> | 41862 | &nbsp;&nbsp; $389735 |
| AbbVie, Inc. | 59784 | &nbsp;&nbsp; 13002422 |
| Abcuro, Inc., Series C<sup>(a)(b)</sup> | 241900 | &nbsp;&nbsp; 933734 |
| Abivax SA, ADR<sup>(a)</sup> | 8695 | &nbsp;&nbsp; 968188 |
| Agios Pharmaceuticals, Inc.<sup>(a)</sup> | 99595 | &nbsp;&nbsp; 3369299 |
| Akeso, Inc.<sup>(a)(c)</sup> | 204000 | &nbsp;&nbsp; 3473489 |
| Aktis Oncology, Inc.<sup>(a)</sup> | 58563 | &nbsp;&nbsp; 1047692 |
| Allogene Therapeutics, Inc.<sup>(a)</sup> | 348877 | &nbsp;&nbsp; 851260 |
| Amgen, Inc.<sup>(d)</sup> | 45282 | &nbsp;&nbsp; 15932472 |
| Apogee Therapeutics, Inc.<sup>(a)</sup> | 40862 | &nbsp;&nbsp; 3439355 |
| Arcellx, Inc.<sup>(a)</sup> | 31135 | &nbsp;&nbsp; 3574921 |
| Arcus Biosciences, Inc.<sup>(a)</sup> | 165805 | &nbsp;&nbsp; 3581388 |
| Argenx SE, ADR<sup>(a)</sup> | 11933 | &nbsp;&nbsp; 8714073 |
| Ascendis Pharma A/S, ADR<sup>(a)</sup> | 4166 | &nbsp;&nbsp; 952889 |
| Avalo Therapeutics, Inc.<sup>(a)</sup> | 30621 | &nbsp;&nbsp; 457172 |
| Beam Therapeutics, Inc.<sup>(a)</sup> | 76864 | &nbsp;&nbsp; 1831669 |
| Bicara Therapeutics, Inc.<sup>(a)</sup> | 52958 | &nbsp;&nbsp; 1053335 |
| Biogen, Inc.<sup>(a)(d)</sup> | 137487 | &nbsp;&nbsp; 25205492 |
| Biohaven Ltd.<sup>(a)</sup> | 46808 | &nbsp;&nbsp; 395996 |
| BioMarin Pharmaceutical, Inc.<sup>(a)</sup> | 31662 | &nbsp;&nbsp; 1788586 |
| BioNTech SE, ADR<sup>(a)</sup> | 11340 | &nbsp;&nbsp; 1007899 |
| BridgeBio Oncology Therapeutics, Inc.<sup>(a)</sup> | 263669 | &nbsp;&nbsp; 2359838 |
| Bridgebio Pharma, Inc.<sup>(a)</sup> | 136783 | &nbsp;&nbsp; 10157506 |
| Bright Minds Biosciences, Inc.<sup>(a)</sup> | 31933 | &nbsp;&nbsp; 2330151 |
| Cogent Biosciences, Inc.<sup>(a)</sup> | 262694 | &nbsp;&nbsp; 10111092 |
| Corvus Pharmaceuticals, Inc.<sup>(a)</sup> | 24771 | &nbsp;&nbsp; 362400 |
| Cytokinetics, Inc.<sup>(a)</sup> | 17061 | &nbsp;&nbsp; 1124490 |
| CytomX Therapeutics, Inc.<sup>(a)</sup> | 215748 | &nbsp;&nbsp; 1014016 |
| Denali Therapeutics, Inc.<sup>(a)(e)</sup> | 78053 | &nbsp;&nbsp; 1498618 |
| Dianthus Therapeutics, Inc.<sup>(a)</sup> | 62279 | &nbsp;&nbsp; 5226454 |
| Dyne Therapeutics, Inc.<sup>(a)</sup> | 80931 | &nbsp;&nbsp; 1467279 |
| Eikon Therapeutics, Inc.<sup>(a)(e)</sup> | 121628 | &nbsp;&nbsp; 1286824 |
| Enanta Pharmaceuticals, Inc.<sup>(a)</sup> | 69729 | &nbsp;&nbsp; 880677 |
| Erasca, Inc.<sup>(a)</sup> | 159240 | &nbsp;&nbsp; 2576503 |
| Exelixis, Inc.<sup>(a)</sup> | 210176 | &nbsp;&nbsp; 9014449 |
| Genmab A/S<sup>(a)</sup> | 58159 | &nbsp;&nbsp; 15663462 |
| Gilead Sciences, Inc.<sup>(d)</sup> | 214745 | &nbsp;&nbsp; 29929011 |
| Gossamer Bio, Inc.<sup>(a)</sup> | 60195 | &nbsp;&nbsp; 19774 |
| Halozyme Therapeutics, Inc.<sup>(a)</sup> | 63226 | &nbsp;&nbsp; 4086296 |
| Immunocore Holdings PLC, ADR<sup>(a)</sup> | 37226 | &nbsp;&nbsp; 1122364 |
| Immunocore Ltd., Series C, ADR<sup>(a)</sup> | 321900 | &nbsp;&nbsp; 9705285 |
| Immunome, Inc.<sup>(a)</sup> | 71450 | &nbsp;&nbsp; 1562611 |
| Incyte Corp.<sup>(a)</sup> | 40489 | &nbsp;&nbsp; 3810825 |
| Insmed, Inc.<sup>(a)</sup> | 36385 | &nbsp;&nbsp; 5949675 |
| Intellia Therapeutics, Inc.<sup>(a)(e)</sup> | 131520 | &nbsp;&nbsp; 1686086 |
| Ionis Pharmaceuticals, Inc.<sup>(a)</sup> | 70173 | &nbsp;&nbsp; 5269291 |
| &nbsp;&nbsp;&nbsp; Kailera Therapeutics, Inc., Series B, (Acquired <br> 10/31/25, Cost: $3,504,004)<sup>(a)(b)(f)</sup><br>| 250286 | &nbsp;&nbsp; 3504004 |
| KalVista Pharmaceuticals, Inc.<sup>(a)</sup> | 70390 | &nbsp;&nbsp; 1416951 |
| Kiniksa Pharmaceuticals International PLC<sup>(a)</sup> | 64037 | &nbsp;&nbsp; 3083382 |
| Kodiak Sciences, Inc.<sup>(a)</sup> | 21542 | &nbsp;&nbsp; 821181 |
| Kymera Therapeutics, Inc.<sup>(a)</sup> | 13937 | &nbsp;&nbsp; 1160813 |
| Moderna, Inc.<sup>(a)(d)</sup> | 549814 | &nbsp;&nbsp; 27930551 |
| Monte Rosa Therapeutics, Inc.<sup>(a)</sup> | 70406 | &nbsp;&nbsp; 1158179 |
| MoonLake Immunotherapeutics<sup>(a)</sup> | 43395 | &nbsp;&nbsp; 808883 |
| Natera, Inc.<sup>(a)</sup> | 82862 | &nbsp;&nbsp; 16571571 |
| Neurocrine Biosciences, Inc.<sup>(a)</sup> | 79676 | &nbsp;&nbsp; 10496516 |
| Neurogene, Inc.<sup>(a)</sup> | 36199 | &nbsp;&nbsp; 729772 |
| Nuvalent, Inc., Class A<sup>(a)</sup> | 52024 | &nbsp;&nbsp; 5329859 |

---

---

| | | |
|:---|:---|:---|
| *Security* | <br> *Shares*<br>| *Value* |
| **Biotechnology (continued)** | **Biotechnology (continued)** |  |
| ORIC Pharmaceuticals, Inc.<sup>(a)</sup> | 99005 | &nbsp;&nbsp; $1254393 |
| Oruka Therapeutics, Inc.<sup>(a)</sup> | 48426 | &nbsp;&nbsp; 2375295 |
| Palvella Therapeutics, Inc.<sup>(a)</sup> | 21246 | &nbsp;&nbsp; 2648314 |
| Protagonist Therapeutics, Inc.<sup>(a)</sup> | 68855 | &nbsp;&nbsp; 7257317 |
| PTC Therapeutics, Inc.<sup>(a)</sup> | 34361 | &nbsp;&nbsp; 2341015 |
| REGENXBIO, Inc.<sup>(a)</sup> | 81282 | &nbsp;&nbsp; 681143 |
| ReNAgade Therapeutics, Inc., Series A-2<sup>(a)(b)</sup> | 3584906 | &nbsp;&nbsp; 13049058 |
| Revolution Medicines, Inc.<sup>(a)</sup> | 46968 | &nbsp;&nbsp; 4567638 |
| Rhythm Pharmaceuticals, Inc.<sup>(a)</sup> | 111452 | &nbsp;&nbsp; 9692980 |
| Roivant Sciences Ltd.<sup>(a)</sup> | 240456 | &nbsp;&nbsp; 6660631 |
| Sagimet Biosciences, Inc., Series A<sup>(a)(e)</sup> | 220227 | &nbsp;&nbsp; 1150686 |
| Scholar Rock Holding Corp.<sup>(a)</sup> | 30077 | &nbsp;&nbsp; 1478585 |
| Stoke Therapeutics, Inc.<sup>(a)</sup> | 132656 | &nbsp;&nbsp; 4319279 |
| Summit Therapeutics, Inc.<sup>(a)(e)</sup> | 116250 | &nbsp;&nbsp; 2204100 |
| Syndax Pharmaceuticals, Inc.<sup>(a)</sup> | 24320 | &nbsp;&nbsp; 568115 |
| TScan Therapeutics, Inc.<sup>(a)</sup> | 407010 | &nbsp;&nbsp; 411080 |
| United Therapeutics Corp.<sup>(a)</sup> | 3080 | &nbsp;&nbsp; 1826378 |
| Upstream Bio, Inc.<sup>(a)</sup> | 56530 | &nbsp;&nbsp; 508770 |
| Vertex Pharmaceuticals, Inc.<sup>(a)</sup> | 20900 | &nbsp;&nbsp; 9332686 |
| Viking Therapeutics, Inc.<sup>(a)</sup> | 56322 | &nbsp;&nbsp; 1832718 |
| Viridian Therapeutics, Inc.<sup>(a)</sup> | 173120 | &nbsp;&nbsp; 3386227 |
| Vor BioPharma, Inc.<sup>(a)</sup> | 43710 | &nbsp;&nbsp; 779786 |
| Voyager Therapeutics, Inc.<sup>(a)</sup> | 141787 | &nbsp;&nbsp; 547298 |
| Zealand Pharma A/S<sup>(a)</sup> | 46920 | &nbsp;&nbsp; 2185064 |
|  |  | &nbsp;&nbsp; 374256261 |
| **Health Care Equipment & Supplies — 9.9%** | **Health Care Equipment & Supplies — 9.9%** |  |
| Abbott Laboratories<sup>(d)</sup> | 68889 | &nbsp;&nbsp; 7072834 |
| Boston Scientific Corp.<sup>(a)(d)</sup> | 151277 | &nbsp;&nbsp; 9492632 |
| Dexcom, Inc.<sup>(a)(d)</sup> | 173259 | &nbsp;&nbsp; 10880665 |
| Edwards Lifesciences Corp.<sup>(a)(d)</sup> | 277879 | &nbsp;&nbsp; 22252550 |
| &nbsp;&nbsp;&nbsp; EXO Imaging, Inc., (Acquired 06/24/21, Cost: <br> $13,225,003)<sup>(a)(b)(f)</sup><br>| 22576 | &nbsp;&nbsp; 8353 |
| Glaukos Corp.<sup>(a)</sup> | 12098 | &nbsp;&nbsp; 1302471 |
| Hologic, Inc.<sup>(a)</sup> | 137197 | &nbsp;&nbsp; 10370721 |
| Insulet Corp.<sup>(a)</sup> | 21493 | &nbsp;&nbsp; 4510091 |
| Intuitive Surgical, Inc.<sup>(a)</sup> | 23573 | &nbsp;&nbsp; 10866917 |
| Lantheus Holdings, Inc.<sup>(a)</sup> | 48294 | &nbsp;&nbsp; 3663100 |
| Medline, Inc., Class A<sup>(a)</sup> | 141863 | &nbsp;&nbsp; 6312904 |
| Medtronic PLC | 115270 | &nbsp;&nbsp; 9988146 |
| Novocure Ltd.<sup>(a)</sup> | 210016 | &nbsp;&nbsp; 2289174 |
| &nbsp;&nbsp;&nbsp; Nucleix Ltd., (Acquired 04/10/24, Cost: <br> $1,300,000)<sup>(a)(b)(f)</sup><br>| 1300 | &nbsp;&nbsp; 1030276 |
| Nyxoah SA<sup>(a)(e)</sup> | 112019 | &nbsp;&nbsp; 327095 |
|  |  | &nbsp;&nbsp; 100367929 |
| **Health Care Providers & Services**<sup>(a)</sup> **— 2.3%** | **Health Care Providers & Services**<sup>(a)</sup> **— 2.3%** |  |
| Guardant Health, Inc.<sup>(d)</sup> | 221348 | &nbsp;&nbsp; 20445915 |
| RadNet, Inc.<sup>(e)</sup> | 46906 | &nbsp;&nbsp; 2621576 |
|  |  | &nbsp;&nbsp; 23067491 |
| **Life Sciences Tools & Services — 10.9%** | **Life Sciences Tools & Services — 10.9%** |  |
| Agilent Technologies, Inc. | 112566 | &nbsp;&nbsp; 12830273 |
| Bio-Rad Laboratories, Inc., Class A<sup>(a)(e)</sup> | 17608 | &nbsp;&nbsp; 4908230 |
| Bio-Techne Corp. | 169594 | &nbsp;&nbsp; 8862982 |
| Bruker Corp. | 64684 | &nbsp;&nbsp; 2336386 |
| Charles River Laboratories International, Inc.<sup>(a)(e)</sup> | 60883 | &nbsp;&nbsp; 10502318 |
| Danaher Corp. | 53519 | &nbsp;&nbsp; 10147202 |
| Illumina, Inc.<sup>(a)</sup> | 116338 | &nbsp;&nbsp; 14339822 |
| IQVIA Holdings, Inc.<sup>(a)</sup> | 46747 | &nbsp;&nbsp; 7972233 |
| Lonza Group AG, Registered Shares | 23258 | &nbsp;&nbsp; 14920434 |
| Qiagen NV | 85732 | &nbsp;&nbsp; 3432709 |
| Tempus AI, Inc., Class A<sup>(a)(e)</sup> | 77823 | &nbsp;&nbsp; 3519156 |

---

------

Schedule of Investments (unaudited)(continued)

March 31, 2026

**BlackRock Health Sciences Term Trust (BMEZ)** 

**(Percentages shown are based on Net Assets)**

---

| | | |
|:---|:---|:---|
| *Security* | <br> *Shares*<br>| *Value* |
| **Life Sciences Tools & Services (continued)** | **Life Sciences Tools & Services (continued)** |  |
| Thermo Fisher Scientific, Inc. | 15447 | &nbsp;&nbsp; $7592664 |
| Waters Corp.<sup>(a)</sup> | 14015 | &nbsp;&nbsp; 4173667 |
| Wuxi Biologics Cayman, Inc.<sup>(a)(c)</sup> | 1152500 | &nbsp;&nbsp; 4956317 |
|  |  | &nbsp;&nbsp; 110494393 |
| **Pharmaceuticals — 23.2%** | **Pharmaceuticals — 23.2%** |  |
| Alumis, Inc.<sup>(a)</sup> | 101619 | &nbsp;&nbsp; 2238667 |
| Arvinas, Inc.<sup>(a)</sup> | 94854 | &nbsp;&nbsp; 1005452 |
| AstraZeneca PLC | 57869 | &nbsp;&nbsp; 11412924 |
| Axsome Therapeutics, Inc.<sup>(a)</sup> | 28760 | &nbsp;&nbsp; 4861015 |
| Bristol-Myers Squibb Co. | 177819 | &nbsp;&nbsp; 10784722 |
| Daiichi Sankyo Co. Ltd. | 93900 | &nbsp;&nbsp; 1679933 |
| Edgewise Therapeutics, Inc.<sup>(a)(e)</sup> | 89151 | &nbsp;&nbsp; 2808257 |
| Eisai Co. Ltd. | 304900 | &nbsp;&nbsp; 9545445 |
| Elanco Animal Health, Inc.<sup>(a)(e)</sup> | 210509 | &nbsp;&nbsp; 5037480 |
| Enliven Therapeutics, Inc.<sup>(a)</sup> | 54885 | &nbsp;&nbsp; 2151492 |
| EyePoint, Inc.<sup>(a)</sup> | 75092 | &nbsp;&nbsp; 967936 |
| Galderma Group AG | 29482 | &nbsp;&nbsp; 5794206 |
| GSK PLC | 521765 | &nbsp;&nbsp; 14372267 |
| GSK PLC, ADR | 112532 | &nbsp;&nbsp; 6210641 |
| Johnson & Johnson<sup>(d)</sup> | 145639 | &nbsp;&nbsp; 35599996 |
| LB Pharmaceuticals, Inc.<sup>(a)</sup> | 207987 | &nbsp;&nbsp; 5128959 |
| Maze Therapeutics, Inc.<sup>(a)</sup> | 44725 | &nbsp;&nbsp; 1335041 |
| MBX Biosciences, Inc.<sup>(a)</sup> | 128549 | &nbsp;&nbsp; 3837188 |
| Merck & Co., Inc.<sup>(d)</sup> | 262388 | &nbsp;&nbsp; 31562653 |
| Novartis AG, Class N, Registered Shares | 104397 | &nbsp;&nbsp; 16024346 |
| Nuvation Bio, Inc., Class A<sup>(a)</sup> | 283833 | &nbsp;&nbsp; 1217644 |
| Ocular Therapeutix, Inc.<sup>(a)</sup> | 76913 | &nbsp;&nbsp; 651453 |
| Pfizer, Inc. | 538786 | &nbsp;&nbsp; 15129111 |
| Roche Holding AG | 42839 | &nbsp;&nbsp; 17096653 |
| Terns Pharmaceuticals, Inc.<sup>(a)</sup> | 155371 | &nbsp;&nbsp; 8191159 |
| Teva Pharmaceutical Industries Ltd., ADR<sup>(a)</sup> | 212205 | &nbsp;&nbsp; 6391615 |
| UCB SA | 44287 | &nbsp;&nbsp; 13343531 |
| WaVe Life Sciences Ltd.<sup>(a)</sup> | 96283 | &nbsp;&nbsp; 698052 |
|  |  | &nbsp;&nbsp; 235077838 |
| **Total Common Stocks — 83.3%** <br>**(Cost: $749,175,409)** | **Total Common Stocks — 83.3%** <br>**(Cost: $749,175,409)** | &nbsp;&nbsp; 843263912 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | |
|:---|:---|:---|
|  | *Benefical* <br>*Interest (000)*<br>|  |
| **Other Interests** | **Other Interests** | **Other Interests** |
| **Biotechnology**<sup>(b)(f)(g)</sup> **— 0.1%** | **Biotechnology**<sup>(b)(f)(g)</sup> **— 0.1%** |  |
| Affinivax, Inc., (Acquired 08/18/22, Cost: $—) | $183 | &nbsp;&nbsp; 672212 |
| &nbsp;&nbsp;&nbsp; Amunix Pharmaceuticals, Inc., (Acquired 02/08/22, <br> Cost: $—)<br>| 5657 | &nbsp;&nbsp; 169712 |
| **Total Other Interests — 0.1%** <br>**(Cost: $—)** | **Total Other Interests — 0.1%** <br>**(Cost: $—)** | &nbsp;&nbsp; 841924 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | |
|:---|:---|:---|
|  | <br>*Shares*<br>|  |
| **Preferred Securities** | **Preferred Securities** | **Preferred Securities** |
| **Preferred Stocks — 12.6%** | **Preferred Stocks — 12.6%** | **Preferred Stocks — 12.6%** |
| **Biotechnology**<sup>(b)</sup> **— 7.0%** | **Biotechnology**<sup>(b)</sup> **— 7.0%** |  |
| Abcuro, Inc., Series B<sup>(a)</sup> | 1092954 | &nbsp;&nbsp; 1136672 |
| &nbsp;&nbsp;&nbsp; Adarx Pharamaceuticals, Inc., Series C, (Acquired <br> 08/02/23, Cost: $7,160,001)<sup>(a)(f)</sup><br>| 860577 | &nbsp;&nbsp; 11282164 |

---

---

| | | |
|:---|:---|:---|
| *Security* | <br> *Shares*<br>| *Value* |
| **Biotechnology (continued)** | **Biotechnology (continued)** |  |
| &nbsp;&nbsp;&nbsp; Angitia Biopharmaceuticals Ltd., Series D, (Acquired <br> 01/27/26, Cost: $2,923,903)<sup>(a)(f)</sup><br>| 296024 | &nbsp;&nbsp; $2927677 |
| &nbsp;&nbsp;&nbsp; Bright Peak Therapeutics, Inc., Series B, (Acquired <br> 05/14/21, Cost: $8,000,004)<sup>(a)(f)</sup><br>| 3191830 | &nbsp;&nbsp; 2393873 |
| &nbsp;&nbsp;&nbsp; Cellarity, Inc., Series B, Class B, (Acquired 01/15/21, <br> Cost: $14,584,998)<sup>(a)(f)</sup><br>| 2430833 | &nbsp;&nbsp; 5931233 |
| &nbsp;&nbsp;&nbsp; Genesis Therapeutics, Inc., Series B, (Acquired <br> 08/10/23, Cost: $6,999,996)<sup>(a)(f)</sup><br>| 1370506 | &nbsp;&nbsp; 7496668 |
| &nbsp;&nbsp;&nbsp; Goldfinch Bio, Inc., Series B, (Acquired 06/26/20, <br> Cost: $3,561,633)<sup>(a)(f)</sup><br>| 3409215 | &nbsp;&nbsp; 1022765 |
| Kartos Therapeutics, Inc.<sup>(a)(f)</sup> <br>|  |  |
| &nbsp;&nbsp;&nbsp; (Acquired 02/12/26, Cost: $531,322) | 531322 | &nbsp;&nbsp; 533766 |
| &nbsp;&nbsp;&nbsp; Series C, (Acquired 08/22/23, Cost: $7,539,875) | 1333783 | &nbsp;&nbsp; 7575887 |
| &nbsp;&nbsp;&nbsp; Series D, (Acquired 02/19/25, Cost: $2,074,436) | 366962 | &nbsp;&nbsp; 2084344 |
| &nbsp;&nbsp;&nbsp; Laronde, Inc., Series B, (Acquired 07/28/21, Cost: <br> $13,498,156)<sup>(a)(f)</sup><br>| 482077 | &nbsp;&nbsp; 9313728 |
| Mirvie, Inc.<sup>(a)</sup> <br>|  |  |
| &nbsp;&nbsp;&nbsp; Series B, (Acquired 10/15/21, Cost: $6,250,000)<sup>(f)</sup> | 2793833 | &nbsp;&nbsp; 4134873 |
| &nbsp;&nbsp;&nbsp; Series C | 724806 | &nbsp;&nbsp; 1630814 |
| &nbsp;&nbsp;&nbsp; NiKang Therapeutics, Inc., Series C, (Acquired <br> 05/20/21, Cost: $7,999,996)<sup>(a)(f)</sup><br>| 1394189 | &nbsp;&nbsp; 5339744 |
| &nbsp;&nbsp;&nbsp; Numab Therapeutics AG, Series C, (Acquired <br> 05/07/21, Cost: $9,204,219)<sup>(f)</sup><br>| 1139305 | &nbsp;&nbsp; 8107360 |
|  |  | &nbsp;&nbsp; 70911568 |
| **Health Care Equipment & Supplies**<sup>(a)(b)(f)</sup> **— 0.8%** | **Health Care Equipment & Supplies**<sup>(a)(b)(f)</sup> **— 0.8%** |  |
| &nbsp;&nbsp;&nbsp; EXO Imaging, Inc., Series D, (Acquired 07/24/24, <br> Cost: $640,450)<br>| 1053928 | &nbsp;&nbsp; 779907 |
| &nbsp;&nbsp;&nbsp; Nucleix Ltd., Series AA, (Acquired 03/25/21, Cost: <br> $6,929,998)<br>| 2379480 | &nbsp;&nbsp; 1570457 |
| &nbsp;&nbsp;&nbsp; Quanta Dialysis Technologies Ltd., Series D, <br> (Acquired 06/18/21, Cost: $14,071,890)<br>| 115766240 | &nbsp;&nbsp; 5516217 |
| &nbsp;&nbsp;&nbsp; Swift Health Systems, Inc., Series D, (Acquired <br> 08/27/21, Cost: $6,441,930)<br>| 2078 | &nbsp;&nbsp; 4634 |
|  |  | &nbsp;&nbsp; 7871215 |
| **Health Care Providers & Services — 0.5%** | **Health Care Providers & Services — 0.5%** |  |
| &nbsp;&nbsp;&nbsp; Everly Well, Inc., Series D, (Acquired 11/25/20, Cost: <br> $9,999,986)<sup>(a)(b)(f)</sup><br>| 382775 | &nbsp;&nbsp; 5022008 |
| **Life Sciences Tools & Services — 1.2%** | **Life Sciences Tools & Services — 1.2%** |  |
| Sartorius AG | 47229 | &nbsp;&nbsp; 11817487 |
| **Pharmaceuticals**<sup>(a)(b)(f)</sup> **— 0.8%** | **Pharmaceuticals**<sup>(a)(b)(f)</sup> **— 0.8%** |  |
| Insitro, Inc. |  |  |
| &nbsp;&nbsp;&nbsp; Series B, (Acquired 05/21/20, Cost: $5,000,000) | 802478 | &nbsp;&nbsp; 6708716 |
| &nbsp;&nbsp;&nbsp; Series C, (Acquired 03/10/21, Cost: $3,600,018) | 196818 | &nbsp;&nbsp; 1645398 |
|  |  | &nbsp;&nbsp; 8354114 |
| **Semiconductors & Semiconductor Equipment — 2.3%** | **Semiconductors & Semiconductor Equipment — 2.3%** |  |
| &nbsp;&nbsp;&nbsp; PsiQuantum Corp., Series D, (Acquired 05/21/21, <br> Cost: $14,999,996)<sup>(a)(b)(f)</sup><br>| 571947 | &nbsp;&nbsp; 23650008 |
|  |  | &nbsp;&nbsp; 127626400 |
| **Total Preferred Securities — 12.6%** <br>**(Cost: $172,208,659)** | **Total Preferred Securities — 12.6%** <br>**(Cost: $172,208,659)** | &nbsp;&nbsp; 127626400 |
| **Rights** | **Rights** | **Rights** |
| **Biotechnology**<sup>(b)</sup> **— 0.0%** | **Biotechnology**<sup>(b)</sup> **— 0.0%** |  |
| Blueprint Medicines Corp., CVR | 36582 | &nbsp;&nbsp; 36582 |
| Korro Bio, Inc., CVR | 231775 | &nbsp;&nbsp; 2 |

---

Schedule of Investments

------

Schedule of Investments (unaudited)(continued)

March 31, 2026

**BlackRock Health Sciences Term Trust (BMEZ)** 

**(Percentages shown are based on Net Assets)**

---

| | | |
|:---|:---|:---|
| *Security* | <br> *Shares*<br>| *Value* |
| **Biotechnology (continued)** | **Biotechnology (continued)** |  |
| Mirati Therapeutics, Inc. CVR<sup>(e)</sup> | 180175 | &nbsp;&nbsp; $142338 |
| Vigil Neuroscience, Inc., CVR | 131344 | &nbsp;&nbsp; 6567 |
|  |  | &nbsp;&nbsp; 185489 |
| **Health Care Equipment & Supplies — 0.0%** | **Health Care Equipment & Supplies — 0.0%** |  |
| Abiomed, Inc., CVR<sup>(b)</sup> | 98636 | &nbsp;&nbsp; 228836 |
| **Total Rights — 0.0%** <br>**(Cost: $250,126)** | **Total Rights — 0.0%** <br>**(Cost: $250,126)** | &nbsp;&nbsp; 414325 |
| **Warrants** | **Warrants** | **Warrants** |
| **Biotechnology — 0.0%** | **Biotechnology — 0.0%** |  |
| &nbsp;&nbsp;&nbsp; Goldfinch Ltd., (Issued/Exercisable 02/10/26, 1 Share <br> for 1 Warrant, Expires 11/20/35, Strike Price USD <br> 1.18)<sup>(a)(b)</sup><br>| 441503 | &nbsp;&nbsp; 4 |
| **Total Warrants — 0.0%** <br>**(Cost: $461,242)** | **Total Warrants — 0.0%** <br>**(Cost: $461,242)** | &nbsp;&nbsp; 4 |
| **Total Long-Term Investments — 96.0%** <br>**(Cost: $922,095,436)** | **Total Long-Term Investments — 96.0%** <br>**(Cost: $922,095,436)** | &nbsp;&nbsp; 972146565 |
| **Short-Term Securities** | **Short-Term Securities** | **Short-Term Securities** |
| **Money Market Funds — 5.6%** | **Money Market Funds — 5.6%** |  |
| &nbsp;&nbsp;&nbsp; BlackRock Cash Funds: Institutional, SL Agency <br> Shares, 3.77%<sup>(h)(i)(j)</sup><br>| 7754002 | &nbsp;&nbsp; 7755553 |
| &nbsp;&nbsp;&nbsp; BlackRock Liquidity Funds, T-Fund, Institutional <br> Shares, 3.55%<sup>(h)(i)</sup><br>| 48671382 | &nbsp;&nbsp; 48671382 |
| **Total Short-Term Securities — 5.6%** <br>**(Cost: $56,426,935)** | **Total Short-Term Securities — 5.6%** <br>**(Cost: $56,426,935)** | &nbsp;&nbsp; 56426935 |
| **Total Investments — 101.6%** <br>**(Cost: $978,522,371)** | **Total Investments — 101.6%** <br>**(Cost: $978,522,371)** | &nbsp;&nbsp; 1028573500 |
| **Liabilities in Excess of Other Assets — (1.6)%** | **Liabilities in Excess of Other Assets — (1.6)%** | &nbsp;&nbsp; (15968671)<br>|
| **Net Assets — 100.0%** | **Net Assets — 100.0%** | &nbsp;&nbsp; $1012604829 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<sup>(a)</sup> Non-income producing security.

<sup>(b)</sup> Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy. 

<sup>(c)</sup> Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors. 

<sup>(d)</sup> All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written. 

<sup>(e)</sup> All or a portion of this security is on loan.

<sup>(f)</sup> Restricted security as to resale, excluding 144A securities. The Trust held restricted securities with a current value of $118,425,984, representing 11.7% of its net assets as of period end, and an original cost of $170,041,814. 

<sup>(g)</sup> Other interests represent beneficial interests in liquidation trusts and other reorganization or private entities. 

<sup>(h)</sup> Affiliate of the Trust.

<sup>(i)</sup> Annualized 7-day yield as of period end.

<sup>(j)</sup> All or a portion of this security was purchased with the cash collateral from loaned securities. 

For purposes of this report, industry and sector sub-classifications may differ from those utilized by the Trust for compliance purposes.

**Affiliates**

Investments in issuers considered to be affiliate(s) of the Trust during the period ended March 31, 2026 for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| *Affiliated Issuer* | *Value at* <br>*12/31/25*<br>| *Proceeds* <br>*from Sales*<br>| *Net* <br>*Realized* <br>*Gain (Loss)*<br>| *Change in* <br>*Unrealized* <br>*Appreciation* <br>*(Depreciation)*<br>| *Value at* <br>*03/31/26*<br>| *Shares* <br>*Held at* <br>*03/31/26*<br>| *Income* | *Capital Gain* <br>*Distributions* <br>*from* <br>*Underlying* <br>*Funds*<br>|
| BlackRock Cash Funds: Institutional, SL Agency Shares | $4824349<br> $2932071 <br><sup>(a)</sup><br>| &nbsp;&nbsp; $— | $(867)<br>| $— | $7755553 | 7754002 | $10621 <br><sup>(b)</sup><br>| &nbsp;&nbsp; $— |
| BlackRock Liquidity Funds, T-Fund, Institutional Shares | 17470438<br> 31200944 <br><sup>(a)</sup><br>| &nbsp;&nbsp; — |  |  | 48671382 | 48671382 | 213625 | &nbsp;&nbsp; — |
|  |  |  | $(867)<br>| $— | $56426935 |  | $224246 | &nbsp;&nbsp; $— |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<sup>(a)</sup> Represents net amount purchased (sold).

<sup>(b)</sup> All or a portion represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of collateral investment fees, and other payments to and from borrowers of securities. 

------

Schedule of Investments (unaudited)(continued)

March 31, 2026

**BlackRock Health Sciences Term Trust (BMEZ)** 

**Fair Value Hierarchy as of Period End**

Various inputs are used in determining the fair value of financial instruments at the measurement date. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 1 – Unadjusted price quotations in active markets/exchanges that the Trust has the ability to access for identical assets or liabilities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Level 3 – Inputs that are unobservable and significant to the entire fair value measurement for the asset or liability (including the Valuation Committee's assumptions used in determining the fair value of financial instruments).

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the Valuation Committee in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by privately held companies or funds that may not have a secondary market and/or may have a limited number of investors. The categorization of a value determined for financial instruments is based on the pricing transparency of the financial instruments and is not necessarily an indication of the risks associated with investing in those securities. For information about the Trust's policy regarding valuation of financial instruments, refer to its most recent financial statements.

The following table summarizes the Trust's financial instruments categorized in the fair value hierarchy. The breakdown of the Trust's financial instruments into major categories is disclosed in the Schedule of Investments above.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | *Level 1* | *Level 2* | *Level 3* | *Total* |
| Assets |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Investments  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Long-Term Investments  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common Stocks  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Biotechnology | &nbsp;&nbsp; $325742165 | &nbsp;&nbsp;&nbsp;&nbsp; $31027300 | &nbsp;&nbsp;&nbsp;&nbsp; $17486796 | &nbsp;&nbsp;&nbsp;&nbsp; $374256261 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Health Care Equipment & Supplies | &nbsp;&nbsp; 99329300 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 1038629 | &nbsp;&nbsp;&nbsp;&nbsp; 100367929 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Health Care Providers & Services | &nbsp;&nbsp; 23067491 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 23067491 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Life Sciences Tools & Services | &nbsp;&nbsp; 90617642 | &nbsp;&nbsp;&nbsp;&nbsp; 19876751 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 110494393 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharmaceuticals | &nbsp;&nbsp; 157221457 | &nbsp;&nbsp;&nbsp;&nbsp; 77856381 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 235077838 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other Interests | &nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 841924 | &nbsp;&nbsp;&nbsp;&nbsp; 841924 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Preferred Securities |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Preferred Stocks | &nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 11817487 | &nbsp;&nbsp;&nbsp;&nbsp; 115808913 | &nbsp;&nbsp;&nbsp;&nbsp; 127626400 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rights | &nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 414325 | &nbsp;&nbsp;&nbsp;&nbsp; 414325 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Warrants | &nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 4 | &nbsp;&nbsp;&nbsp;&nbsp; 4 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Short-Term Securities  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Money Market Funds | &nbsp;&nbsp; 56426935 | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; — | &nbsp;&nbsp;&nbsp;&nbsp; 56426935 |
|  | &nbsp;&nbsp; $752404990 | &nbsp;&nbsp;&nbsp;&nbsp; $140577919 | &nbsp;&nbsp;&nbsp;&nbsp; $135590591 | &nbsp;&nbsp;&nbsp;&nbsp; $1028573500 |

---

A reconciliation of Level 3 financial instruments is presented when the Trust had a significant amount of Level 3 investments and derivative financial instruments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | *Common* <br>*Stocks*<br>| *Other* <br>*Interests*<br>| *Preferred* <br>*Stocks*<br>| *Rights* | *Warrants* | *Total*  |
| **Assets** |  |  |  |  |  |  |
| Opening balance, as of December 31, 2025 | &nbsp;&nbsp; $15261821 | $2156621 | $126072047 | $412606 | $— | $143903095 |
| Transfers into Level 3 | &nbsp;&nbsp; — |  |  |  |  |  |
| Transfers out of Level 3 | &nbsp;&nbsp; — |  |  |  |  |  |
| Accrued discounts/premiums | &nbsp;&nbsp; — |  |  |  |  |  |
| Net realized gain (loss) | &nbsp;&nbsp; (18325999)<br>|  |  |  |  | (18325999)<br>|
| Net change in unrealized appreciation (depreciation)<sup>(a)</sup> | &nbsp;&nbsp; 21589603 | (1314697)<br>| (12736145)<br>| 1719 | (461237)<br>| 7079243 |
| Purchases | &nbsp;&nbsp; — |  | 3455226 |  | 461241 | 3916467 |
| Sales | &nbsp;&nbsp; — |  | (982215)<br>|  |  | (982215)<br>|
| Closing balance, as of March 31, 2026 | &nbsp;&nbsp; $18525425 | $841924 | $115808913 | $414325 | $4 | $135590591 |
| Net change in unrealized appreciation (depreciation) on investments still held at March 31, 2026<sup>(a)</sup> | &nbsp;&nbsp; $3291197 | $(1314697)<br>| $(12736145)<br>| $1719 | $(461237)<br>| $(11219163)<br>|

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<sup>(a)</sup> Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on investments still held at March 31, 2026 is generally due to investments no longer held or categorized as Level 3 at period end. 

Schedule of Investments

------

Schedule of Investments (unaudited)(continued)

March 31, 2026

**BlackRock Health Sciences Term Trust (BMEZ)** 

The following table summarizes the valuation approaches used and unobservable inputs utilized by the Valuation Committee to determine the value of certain of the Trust's Level 3 financial instruments as of period end. The table does not include Level 3 financial instruments with values based upon unadjusted third-party pricing information in the amount of $6.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | *Value* | &nbsp;&nbsp;&nbsp; *Valuation* <br>*Approach*<br>| &nbsp;&nbsp;&nbsp; *Unobservable* <br>*Inputs*<br>| &nbsp;&nbsp;&nbsp; *Range of* <br>*Unobservable* <br>*Inputs* <br>*Utilized*<sup>(a)</sup> <br>| &nbsp;&nbsp;&nbsp; *Weighted* <br>*Average of* <br>*Unobservable* <br>*Inputs Based* <br>*on Fair Value* <br>|
| **Assets** |  |  |  |  |  |
| Preferred Stocks | &nbsp;&nbsp; $115808913 | Market | Revenue Multiple | 1.88x-8.86x | 2.64x |
|  |  |  | Volatility | 60%-90% | 76% |
|  |  |  | Time to Exit | 1.0 -4.0 years | 2.9 years |
|  |  |  | Market Adjustment Multiple | 0.25x -1.80x | 1.02x |
|  |  | Income | Discount Rate | 4%-19% | 9% |
| Common Stocks | &nbsp;&nbsp; 18525425 | Market | Revenue Multiple | 1.88x |  |
|  |  |  | Volatility | 60% -90% | 83% |
|  |  |  | Time to Exit | 1.0 -3.0 years | 2.5 years |
|  |  |  | Market Adjustment Multiple | 0.25x -0.85x | 0.56x |
|  |  | Income | Discount Rate | 19% |  |
| Other Interests | &nbsp;&nbsp; 841924 | Income | Discount Rate | 4% -4% | 4% |
| Rights | &nbsp;&nbsp; 414323 | Income | Discount Rate | 4% -5% | 4% |
|  | &nbsp;&nbsp; $135590585 |  |  |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<sup>(a)</sup> A significant change in unobservable input could result in a correlated or inverse change in value.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | |
|:---|:---|
| **Portfolio Abbreviation**  | **Portfolio Abbreviation**  |
| ADR | American Depositary Receipt |
| CVR | Contingent Value Right |

---

------

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** BlackRock Health Sciences Term Trust

- **b. Investment Company Act file number:** 811-23466

- **c. CIK number of Registrant:** 0001785971

- **d. LEI of Registrant:** 549300FGMK4EGHSK8N86

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 100 Bellevue Parkway

  - **City:** Wilmington

  - **State:** DE

  - **Foreign country:** US

  - **Zip / Postal Code:** 19809

  - **Telephone number:** 800-441-7762

**Item A.2. Information about the Series.**

- **a. Name of Series:** BlackRock Health Sciences Term Trust

- **c. LEI of Series:** 549300FGMK4EGHSK8N86

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-12-31

- **b. Date as of which information is reported:** 2026-03-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $1037304742.20

**Total Liabilities:** $25092934.33

**Net Assets:** $1012211807.87

**Cash Not Reported:** $34798.98

**Monthly Return Information**

| Class        | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID N/A | 2.07%                | -0.37%               | -4.77%               |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $4676379.20              | $16543537.68                               |
| Month 2  | $-863563.09              | $-2752401.53                               |
| Month 3  | $-11633116.25            | $-41208786.37                              |

**Designated Index Information**

- **Index Name:** MSCI Custom ACWI SMID Growth/Health Care Call Overwrite Index

- **Index Identifier:** N/A

### Schedule of Portfolio Investments

| Name                                         | Title                                                   | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Abbott Laboratories                          | Abbott Laboratories                                     | CUSIP: 002824100<br>LEI: HQD377W2YR662HK5JX27 | Long             | EC               | CORP              | US        |     68889 | NS      | $7072833.63   | 0.70%             |  |  |  | No            |                  1 | On Loan: No      |
| AbbVie Inc                                   | AbbVie Inc                                              | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |     59784 | NS      | $13002422.16  | 1.28%             |  |  |  | No            |                  1 | On Loan: No      |
| Abivax SA                                    | Abivax SA                                               | CUSIP: 00370M103<br>LEI: 969500D8TMNB184OJU95 | Long             | EC               | CORP              | FR        |      8695 | NS      | $968188.25    | 0.10%             |  |  |  | No            |                  1 | On Loan: No      |
| CONTRA ABIOMED INC                           | CONTRA ABIOMED INC                                      | CUSIP: 003CVR016<br>LEI: N/A                  | Long             |  | CORP              | US        |     98636 | NS      | $228835.52    | 0.02%             |  |  |  | No            |                  3 | On Loan: No      |
| Agilent Technologies Inc                     | Agilent Technologies Inc                                | CUSIP: 00846U101<br>LEI: QUIX8Y7A2WP0XRMW7G29 | Long             | EC               | CORP              | US        |    112566 | NS      | $12830272.68  | 1.27%             |  |  |  | No            |                  1 | On Loan: No      |
| Agios Pharmaceuticals Inc                    | Agios Pharmaceuticals Inc                               | CUSIP: 00847X104<br>LEI: 529900ONJHY8EOGYT555 | Long             | EC               | CORP              | US        |     99595 | NS      | $3369298.85   | 0.33%             |  |  |  | No            |                  1 | On Loan: No      |
| Aktis Oncology Inc                           | Aktis Oncology Inc                                      | CUSIP: 01021M104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     58563 | NS      | $1047692.07   | 0.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Allogene Therapeutics Inc                    | Allogene Therapeutics Inc                               | CUSIP: 019770106<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    348877 | NS      | $851259.88    | 0.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Alumis Inc                                   | Alumis Inc                                              | CUSIP: 022307102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    101619 | NS      | $2238666.57   | 0.22%             |  |  |  | No            |                  1 | On Loan: No      |
| Amgen Inc                                    | Amgen Inc                                               | CUSIP: 031162100<br>LEI: 62QBXGPJ34PQ72Z12S66 | Long             | EC               | CORP              | US        |     45282 | NS      | $15932471.70  | 1.57%             |  |  |  | No            |                  1 | On Loan: No      |
| Apogee Therapeutics Inc                      | Apogee Therapeutics Inc                                 | CUSIP: 03770N101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     40862 | NS      | $3439354.54   | 0.34%             |  |  |  | No            |                  1 | On Loan: No      |
| Arcellx Inc                                  | Arcellx Inc                                             | CUSIP: 03940C100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     31135 | NS      | $3574920.70   | 0.35%             |  |  |  | No            |                  1 | On Loan: No      |
| Arcus Biosciences Inc                        | Arcus Biosciences Inc                                   | CUSIP: 03969F109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    165805 | NS      | $3581388.00   | 0.35%             |  |  |  | No            |                  1 | On Loan: No      |
| Argenx SE                                    | Argenx SE                                               | CUSIP: 04016X101<br>LEI: 7245009C5FZE6G9ODQ71 | Long             | EC               | CORP              | NL        |     11933 | NS      | $8714073.25   | 0.86%             |  |  |  | No            |                  1 | On Loan: No      |
| Arvinas Inc                                  | Arvinas Inc                                             | CUSIP: 04335A105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     94854 | NS      | $1005452.40   | 0.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Ascendis Pharma A/S                          | Ascendis Pharma A/S                                     | CUSIP: 04351P101<br>LEI: 549300B66JN3W3J8GH73 | Long             | EC               | CORP              | DK        |      4166 | NS      | $952889.18    | 0.09%             |  |  |  | No            |                  1 | On Loan: No      |
| Autolus Therapeutics PLC                     | Autolus Therapeutics PLC                                | CUSIP: 05280R100<br>LEI: 549300C0KZP8EYROLL02 | Long             | EC               | CORP              | GB        |    135975 | NS      | $187645.50    | 0.02%             |  |  |  | No            |                  1 | On Loan: —       |
| Avalo Therapeutics Inc                       | Avalo Therapeutics Inc                                  | CUSIP: 05338F306<br>LEI: 549300GPK6FPJ3X8SZ39 | Long             | EC               | CORP              | US        |     30621 | NS      | $457171.53    | 0.05%             |  |  |  | No            |                  1 | On Loan: No      |
| Axsome Therapeutics Inc                      | Axsome Therapeutics Inc                                 | CUSIP: 05464T104<br>LEI: 549300EXGR0XLRJEIB95 | Long             | EC               | CORP              | US        |     28760 | NS      | $4861015.20   | 0.48%             |  |  |  | No            |                  1 | On Loan: No      |
| Bicara Therapeutics Inc                      | Bicara Therapeutics Inc                                 | CUSIP: 055477103<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     52958 | NS      | $1053334.62   | 0.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Beam Therapeutics Inc                        | Beam Therapeutics Inc                                   | CUSIP: 07373V105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     76864 | NS      | $1831669.12   | 0.18%             |  |  |  | No            |                  1 | On Loan: No      |
| Bio-Rad Laboratories Inc                     | Bio-Rad Laboratories Inc                                | CUSIP: 090572207<br>LEI: 549300ZC1GPV35XYDK53 | Long             | EC               | CORP              | US        |     17608 | NS      | $4908230.00   | 0.48%             |  |  |  | No            |                  1 | On Loan: —       |
| BioMarin Pharmaceutical Inc                  | BioMarin Pharmaceutical Inc                             | CUSIP: 09061G101<br>LEI: NSLL8ITTRR0J5HEMR848 | Long             | EC               | CORP              | US        |     31662 | NS      | $1788586.38   | 0.18%             |  |  |  | No            |                  1 | On Loan: No      |
| Biogen Inc                                   | Biogen Inc                                              | CUSIP: 09062X103<br>LEI: W8J5WZB5IY3K0NDQT671 | Long             | EC               | CORP              | US        |    137487 | NS      | $25205491.71  | 2.49%             |  |  |  | No            |                  1 | On Loan: No      |
| Bio-Techne Corp                              | Bio-Techne Corp                                         | CUSIP: 09073M104<br>LEI: 54930073RLKQ51TILZ35 | Long             | EC               | CORP              | US        |    169594 | NS      | $8862982.44   | 0.88%             |  |  |  | No            |                  1 | On Loan: No      |
| BioNTech SE                                  | BioNTech SE                                             | CUSIP: 09075V102<br>LEI: 894500UZJ5LG1F8J1U58 | Long             | EC               | CORP              | DE        |     11340 | NS      | $1007899.20   | 0.10%             |  |  |  | No            |                  1 | On Loan: No      |
| CONTRA BLUEPRINT MEDIC                       | CONTRA BLUEPRINT MEDIC                                  | CUSIP: 096CVR048<br>LEI: 5299004CC60O9T5HVM83 | Long             |  | CORP              | US        |     36582 | NS      | $36582.00     | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Boston Scientific Corp                       | Boston Scientific Corp                                  | CUSIP: 101137107<br>LEI: Y6ZDD9FP4P8JSSJMW954 | Long             | EC               | CORP              | US        |    154391 | NS      | $9688035.25   | 0.96%             |  |  |  | No            |                  1 | On Loan: No      |
| BridgeBio Oncology Therapeutics Inc          | BridgeBio Oncology Therapeutics Inc                     | CUSIP: 107924102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    263669 | NS      | $2359837.55   | 0.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Bridgebio Pharma Inc                         | Bridgebio Pharma Inc                                    | CUSIP: 10806X102<br>LEI: 54930028YG89VTY2J114 | Long             | EC               | CORP              | US        |    136783 | NS      | $10157505.58  | 1.00%             |  |  |  | No            |                  1 | On Loan: No      |
| Bright Minds Biosciences Inc                 | Bright Minds Biosciences Inc                            | CUSIP: 10919W405<br>LEI: N/A                  | Long             | EC               | CORP              | CA        |     31933 | NS      | $2330151.01   | 0.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Bristol-Myers Squibb Co                      | Bristol-Myers Squibb Co                                 | CUSIP: 110122108<br>LEI: HLYYNH7UQUORYSJQCN42 | Long             | EC               | CORP              | US        |    177819 | NS      | $10784722.35  | 1.07%             |  |  |  | No            |                  1 | On Loan: No      |
| Bruker Corp                                  | Bruker Corp                                             | CUSIP: 116794108<br>LEI: LEBZ6VLQ6I8XB1NHVY15 | Long             | EC               | CORP              | US        |     64684 | NS      | $2336386.08   | 0.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Charles River Laboratories International Inc | Charles River Laboratories International Inc            | CUSIP: 159864107<br>LEI: 549300BSQ0R4UZ5KX287 | Long             | EC               | CORP              | US        |     60883 | NS      | $10502317.50  | 1.04%             |  |  |  | No            |                  1 | On Loan: —       |
| Cogent Biosciences Inc                       | Cogent Biosciences Inc                                  | CUSIP: 19240Q201<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    138610 | NS      | $5335098.90   | 0.53%             |  |  |  | No            |                  1 | On Loan: No      |
| Corvus Pharmaceuticals Inc                   | Corvus Pharmaceuticals Inc                              | CUSIP: 221015100<br>LEI: 549300I3AVJ8F75NCX65 | Long             | EC               | CORP              | US        |     24771 | NS      | $362399.73    | 0.04%             |  |  |  | No            |                  1 | On Loan: No      |
| Cytokinetics Inc                             | Cytokinetics Inc                                        | CUSIP: 23282W605<br>LEI: 549300BE5DY1HW7IHA64 | Long             | EC               | CORP              | US        |     17061 | NS      | $1124490.51   | 0.11%             |  |  |  | No            |                  1 | On Loan: No      |
| CytomX Therapeutics Inc                      | CytomX Therapeutics Inc                                 | CUSIP: 23284F105<br>LEI: 5493004VW2FW0QLL3345 | Long             | EC               | CORP              | US        |    215748 | NS      | $1014015.60   | 0.10%             |  |  |  | No            |                  1 | On Loan: No      |
| Danaher Corp                                 | Danaher Corp                                            | CUSIP: 235851102<br>LEI: S4BKK9OTCEWQ3YHPFM11 | Long             | EC               | CORP              | US        |     53519 | NS      | $10147202.40  | 1.00%             |  |  |  | No            |                  1 | On Loan: No      |
| Denali Therapeutics Inc                      | Denali Therapeutics Inc                                 | CUSIP: 24823R105<br>LEI: 549300ZTQ2HO18L3Q830 | Long             | EC               | CORP              | US        |     78053 | NS      | $1498617.60   | 0.15%             |  |  |  | No            |                  1 | On Loan: —       |
| Dexcom Inc                                   | Dexcom Inc                                              | CUSIP: 252131107<br>LEI: 549300YSK3QDSFR5EU59 | Long             | EC               | CORP              | US        |    173259 | NS      | $10880665.20  | 1.07%             |  |  |  | No            |                  1 | On Loan: No      |
| Dianthus Therapeutics Inc                    | Dianthus Therapeutics Inc                               | CUSIP: 252828108<br>LEI: 549300Z3N6ODPCOFC890 | Long             | EC               | CORP              | US        |     62279 | NS      | $5226453.68   | 0.52%             |  |  |  | No            |                  1 | On Loan: No      |
| Dyne Therapeutics Inc                        | Dyne Therapeutics Inc                                   | CUSIP: 26818M108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     80931 | NS      | $1467279.03   | 0.14%             |  |  |  | No            |                  1 | On Loan: No      |
| Edgewise Therapeutics Inc                    | Edgewise Therapeutics Inc                               | CUSIP: 28036F105<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     89151 | NS      | $2808256.50   | 0.28%             |  |  |  | No            |                  1 | On Loan: —       |
| Edwards Lifesciences Corp                    | Edwards Lifesciences Corp                               | CUSIP: 28176E108<br>LEI: YA13X31F3V31L8TMPR58 | Long             | EC               | CORP              | US        |    277879 | NS      | $22252550.32  | 2.20%             |  |  |  | No            |                  1 | On Loan: No      |
| Eikon Therapeutics Inc                       | Eikon Therapeutics Inc                                  | CUSIP: 282564103<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    121628 | NS      | $1286824.24   | 0.13%             |  |  |  | No            |                  1 | On Loan: —       |
| Elanco Animal Health Inc                     | Elanco Animal Health Inc                                | CUSIP: 28414H103<br>LEI: 549300SHPNDCE059M934 | Long             | EC               | CORP              | US        |    210509 | NS      | $5037480.37   | 0.50%             |  |  |  | No            |                  1 | On Loan: —       |
| Enanta Pharmaceuticals Inc                   | Enanta Pharmaceuticals Inc                              | CUSIP: 29251M106<br>LEI: 529900SSN4DODDQSN594 | Long             | EC               | CORP              | US        |     69729 | NS      | $880677.27    | 0.09%             |  |  |  | No            |                  1 | On Loan: No      |
| Enliven Therapeutics Inc                     | Enliven Therapeutics Inc                                | CUSIP: 29337E102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     54885 | NS      | $2151492.00   | 0.21%             |  |  |  | No            |                  1 | On Loan: No      |
| Erasca Inc                                   | Erasca Inc                                              | CUSIP: 29479A108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    159240 | NS      | $2576503.20   | 0.25%             |  |  |  | No            |                  1 | On Loan: No      |
| Exelixis Inc                                 | Exelixis Inc                                            | CUSIP: 30161Q104<br>LEI: 254900PJQB59O2O95R37 | Long             | EC               | CORP              | US        |    210176 | NS      | $9014448.64   | 0.89%             |  |  |  | No            |                  1 | On Loan: No      |
| EyePoint Inc                                 | EyePoint Inc                                            | CUSIP: 30233G209<br>LEI: 549300QE1RU34T50MR69 | Long             | EC               | CORP              | US        |     75092 | NS      | $967935.88    | 0.10%             |  |  |  | No            |                  1 | On Loan: No      |
| 4D Molecular Therapeutics Inc                | 4D Molecular Therapeutics Inc                           | CUSIP: 35104E100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     41862 | NS      | $389735.22    | 0.04%             |  |  |  | No            |                  1 | On Loan: No      |
| CONTRA FREQUENCY THERA                       | CONTRA FREQUENCY THERA                                  | CUSIP: 358CVR025<br>LEI: N/A                  | Long             |  | CORP              | US        |    231775 | NS      | $2.32         | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Gilead Sciences Inc                          | Gilead Sciences Inc                                     | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |    214745 | NS      | $29929010.65  | 2.96%             |  |  |  | No            |                  1 | On Loan: No      |
| Glaukos Corp                                 | Glaukos Corp                                            | CUSIP: 377322102<br>LEI: 5299004JA1LHE21M6T14 | Long             | EC               | CORP              | US        |     12098 | NS      | $1302470.68   | 0.13%             |  |  |  | No            |                  1 | On Loan: No      |
| GSK PLC                                      | GSK PLC                                                 | CUSIP: 37733W204<br>LEI: 5493000HZTVUYLO1D793 | Long             | EC               | CORP              | GB        |    112532 | NS      | $6210641.08   | 0.61%             |  |  |  | No            |                  1 | On Loan: No      |
| Gossamer Bio Inc                             | Gossamer Bio Inc                                        | CUSIP: 38341P102<br>LEI: 549300ZOC0N2W6PSFR58 | Long             | EC               | CORP              | US        |     60195 | NS      | $19774.06     | 0.00%             |  |  |  | No            |                  1 | On Loan: No      |
| Guardant Health Inc                          | Guardant Health Inc                                     | CUSIP: 40131M109<br>LEI: 254900M8C3E5VC8BR186 | Long             | EC               | CORP              | US        |    221348 | NS      | $20445914.76  | 2.02%             |  |  |  | No            |                  1 | On Loan: —       |
| Halozyme Therapeutics Inc                    | Halozyme Therapeutics Inc                               | CUSIP: 40637H109<br>LEI: 529900242I3SV9AGM753 | Long             | EC               | CORP              | US        |     63226 | NS      | $4086296.38   | 0.40%             |  |  |  | No            |                  1 | On Loan: No      |
| Hologic Inc                                  | Hologic Inc                                             | CUSIP: 436440101<br>LEI: 549300DYP6F5ZJL0LB74 | Long             | EC               | CORP              | US        |    137197 | NS      | $10370721.23  | 1.02%             |  |  |  | No            |                  1 | On Loan: No      |
| Illumina Inc                                 | Illumina Inc                                            | CUSIP: 452327109<br>LEI: SQ95QG8SR5Q56LSNF682 | Long             | EC               | CORP              | US        |    116338 | NS      | $14339821.88  | 1.42%             |  |  |  | No            |                  1 | On Loan: No      |
| Immunome Inc                                 | Immunome Inc                                            | CUSIP: 45257U108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     71450 | NS      | $1562611.50   | 0.15%             |  |  |  | No            |                  1 | On Loan: No      |
| Immunocore Holdings PLC                      | Immunocore Holdings PLC                                 | CUSIP: 45258D105<br>LEI: 213800IUE3DFS84BVN18 | Long             | EC               | CORP              | GB        |     37226 | NS      | $1122363.90   | 0.11%             |  |  |  | No            |                  1 | On Loan: No      |
| Incyte Corp                                  | Incyte Corp                                             | CUSIP: 45337C102<br>LEI: 549300Z4WN6JVZ3T4680 | Long             | EC               | CORP              | US        |     40489 | NS      | $3810824.68   | 0.38%             |  |  |  | No            |                  1 | On Loan: No      |
| Insmed Inc                                   | Insmed Inc                                              | CUSIP: 457669307<br>LEI: 529900Q55QAG41CCAC11 | Long             | EC               | CORP              | US        |     36385 | NS      | $5949675.20   | 0.59%             |  |  |  | No            |                  1 | On Loan: No      |
| Insulet Corp                                 | Insulet Corp                                            | CUSIP: 45784P101<br>LEI: 549300TZTYD2PYN92D43 | Long             | EC               | CORP              | US        |     21493 | NS      | $4510091.12   | 0.45%             |  |  |  | No            |                  1 | On Loan: No      |
| Intellia Therapeutics Inc                    | Intellia Therapeutics Inc                               | CUSIP: 45826J105<br>LEI: 5493002T5BCPE5DZC723 | Long             | EC               | CORP              | US        |    131520 | NS      | $1686086.40   | 0.17%             |  |  |  | No            |                  1 | On Loan: —       |
| Genmab A/S                                   | Genmab A/S                                              | CUSIP: 000000000<br>LEI: 529900MTJPDPE4MHJ122 | Long             | EC               | CORP              | DK        |     58159 | NS      | $15663461.69  | 1.55%             |  |  |  | No            |                  2 | On Loan: No      |
| Intuitive Surgical Inc                       | Intuitive Surgical Inc                                  | CUSIP: 46120E602<br>LEI: 54930052SRG011710797 | Long             | EC               | CORP              | US        |     23573 | NS      | $10866917.27  | 1.07%             |  |  |  | No            |                  1 | On Loan: No      |
| Ionis Pharmaceuticals Inc                    | Ionis Pharmaceuticals Inc                               | CUSIP: 462222100<br>LEI: 549300SI4ZGLG0BLUZ92 | Long             | EC               | CORP              | US        |     70173 | NS      | $5269290.57   | 0.52%             |  |  |  | No            |                  1 | On Loan: No      |
| IQVIA Holdings Inc                           | IQVIA Holdings Inc                                      | CUSIP: 46266C105<br>LEI: 549300W3R20NM4KQPH86 | Long             | EC               | CORP              | US        |     46747 | NS      | $7972233.38   | 0.79%             |  |  |  | No            |                  1 | On Loan: No      |
| Johnson & Johnson                            | Johnson & Johnson                                       | CUSIP: 478160104<br>LEI: 549300G0CFPGEF6X2043 | Long             | EC               | CORP              | US        |    145639 | NS      | $35599997.16  | 3.52%             |  |  |  | No            |                  1 | On Loan: No      |
| KalVista Pharmaceuticals Inc                 | KalVista Pharmaceuticals Inc                            | CUSIP: 483497103<br>LEI: 529900Q7IDA3WUGRZA51 | Long             | EC               | CORP              | US        |     70390 | NS      | $1416950.70   | 0.14%             |  |  |  | No            |                  1 | On Loan: No      |
| Kodiak Sciences Inc                          | Kodiak Sciences Inc                                     | CUSIP: 50015M109<br>LEI: 254900IXI5NI8C9OQE24 | Long             | EC               | CORP              | US        |     32224 | NS      | $1228378.88   | 0.12%             |  |  |  | No            |                  1 | On Loan: No      |
| Kymera Therapeutics Inc                      | Kymera Therapeutics Inc                                 | CUSIP: 501575104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     13937 | NS      | $1160812.73   | 0.11%             |  |  |  | No            |                  1 | On Loan: No      |
| LB Pharmaceuticals Inc                       | LB Pharmaceuticals Inc                                  | CUSIP: 50180M108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    207987 | NS      | $5128959.42   | 0.51%             |  |  |  | No            |                  1 | On Loan: No      |
| Lantheus Holdings Inc                        | Lantheus Holdings Inc                                   | CUSIP: 516544103<br>LEI: 5299005HUB5IOJGO7S39 | Long             | EC               | CORP              | US        |     48294 | NS      | $3663099.90   | 0.36%             |  |  |  | No            |                  1 | On Loan: No      |
| MBX Biosciences Inc                          | MBX Biosciences Inc                                     | CUSIP: 55287L101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    128549 | NS      | $3837187.65   | 0.38%             |  |  |  | No            |                  1 | On Loan: No      |
| UCB SA                                       | UCB SA                                                  | CUSIP: 000000000<br>LEI: 2138008J191VLSGY5A09 | Long             | EC               | CORP              | BE        |     44287 | NS      | $13343531.19  | 1.32%             |  |  |  | No            |                  2 | On Loan: No      |
| Maze Therapeutics Inc                        | Maze Therapeutics Inc                                   | CUSIP: 578784100<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     44725 | NS      | $1335041.25   | 0.13%             |  |  |  | No            |                  1 | On Loan: No      |
| Sartorius AG                                 | Sartorius AG                                            | CUSIP: 000000000<br>LEI: 529900EQV2DY4FOAMU38 | Long             | EP               | CORP              | DE        |     47229 | NS      | $11817486.81  | 1.17%             |  |  |  | No            |                  2 | On Loan: No      |
| Medline Inc                                  | Medline Inc                                             | CUSIP: 58507V107<br>LEI: 984500FAN6J1P8566D43 | Long             | EC               | CORP              | US        |    141863 | NS      | $6312903.50   | 0.62%             |  |  |  | No            |                  1 | On Loan: No      |
| Merck & Co Inc                               | Merck & Co Inc                                          | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |    262388 | NS      | $31562652.52  | 3.12%             |  |  |  | No            |                  1 | On Loan: No      |
| CONTRA MIRATI THERAPEU                       | CONTRA MIRATI THERAPEU                                  | CUSIP: 604CVR027<br>LEI: 529900GYRW59IDQV6N54 | Long             |  | CORP              | US        |    180175 | NS      | $142338.25    | 0.01%             |  |  |  | No            |                  3 | On Loan: —       |
| Moderna Inc                                  | Moderna Inc                                             | CUSIP: 60770K107<br>LEI: 549300EI6OKH5K5Q2G38 | Long             | EC               | CORP              | US        |    549814 | NS      | $27930551.20  | 2.76%             |  |  |  | No            |                  1 | On Loan: No      |
| Monte Rosa Therapeutics Inc                  | Monte Rosa Therapeutics Inc                             | CUSIP: 61225M102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     70406 | NS      | $1158178.70   | 0.11%             |  |  |  | No            |                  1 | On Loan: No      |
| MoonLake Immunotherapeutics                  | MoonLake Immunotherapeutics                             | CUSIP: 61559X104<br>LEI: N/A                  | Long             | EC               | CORP              | KY        |     28105 | NS      | $523877.20    | 0.05%             |  |  |  | No            |                  1 | On Loan: No      |
| Eisai Co Ltd                                 | Eisai Co Ltd                                            | CUSIP: 000000000<br>LEI: 353800HDEE0ZYEX4QV91 | Long             | EC               | CORP              | JP        |    304900 | NS      | $9545445.15   | 0.94%             |  |  |  | No            |                  2 | On Loan: No      |
| Natera Inc                                   | Natera Inc                                              | CUSIP: 632307104<br>LEI: 529900CQ3OZ0A0VYVU59 | Long             | EC               | CORP              | US        |     82862 | NS      | $16571571.38  | 1.64%             |  |  |  | No            |                  1 | On Loan: No      |
| Neurocrine Biosciences Inc                   | Neurocrine Biosciences Inc                              | CUSIP: 64125C109<br>LEI: 549300FECER0XBN49756 | Long             | EC               | CORP              | US        |     79676 | NS      | $10496516.24  | 1.04%             |  |  |  | No            |                  1 | On Loan: No      |
| Neurogene Inc                                | Neurogene Inc                                           | CUSIP: 64135M105<br>LEI: 529900A7VIY892SZVW73 | Long             | EC               | CORP              | US        |     36199 | NS      | $729771.84    | 0.07%             |  |  |  | No            |                  1 | On Loan: —       |
| Nuvalent Inc                                 | Nuvalent Inc                                            | CUSIP: 670703107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     52024 | NS      | $5329858.80   | 0.53%             |  |  |  | No            |                  1 | On Loan: No      |
| Nuvation Bio Inc                             | Nuvation Bio Inc                                        | CUSIP: 67080N101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    283833 | NS      | $1217643.57   | 0.12%             |  |  |  | No            |                  1 | On Loan: No      |
| Ocular Therapeutix Inc                       | Ocular Therapeutix Inc                                  | CUSIP: 67576A100<br>LEI: 529900ABAWFXOHSIHG03 | Long             | EC               | CORP              | US        |     76913 | NS      | $651453.11    | 0.06%             |  |  |  | No            |                  1 | On Loan: No      |
| ORIC Pharmaceuticals Inc                     | ORIC Pharmaceuticals Inc                                | CUSIP: 68622P109<br>LEI: 54930033FJRNEYBW0L25 | Long             | EC               | CORP              | US        |     99005 | NS      | $1254393.35   | 0.12%             |  |  |  | No            |                  1 | On Loan: No      |
| Oruka Therapeutics Inc                       | Oruka Therapeutics Inc                                  | CUSIP: 687604108<br>LEI: 529900TG7O4ESUDMGI54 | Long             | EC               | CORP              | US        |     48426 | NS      | $2375295.30   | 0.23%             |  |  |  | No            |                  1 | On Loan: No      |
| PTC Therapeutics Inc                         | PTC Therapeutics Inc                                    | CUSIP: 69366J200<br>LEI: 549300UJLWOIWFDGB318 | Long             | EC               | CORP              | US        |     34361 | NS      | $2341014.93   | 0.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Palvella Therapeutics Inc                    | Palvella Therapeutics Inc                               | CUSIP: 697947109<br>LEI: 254900AJDH8PAOOI5T33 | Long             | EC               | CORP              | US        |     21246 | NS      | $2648313.90   | 0.26%             |  |  |  | No            |                  1 | On Loan: No      |
| Novartis AG                                  | Novartis AG                                             | CUSIP: 000000000<br>LEI: 5493007HIVTX6SY6XD66 | Long             | EC               | CORP              | CH        |    104397 | NS      | $16024346.10  | 1.58%             |  |  |  | No            |                  2 | On Loan: No      |
| Pfizer Inc                                   | Pfizer Inc                                              | CUSIP: 717081103<br>LEI: 765LHXWGK1KXCLTFYQ30 | Long             | EC               | CORP              | US        |    538786 | NS      | $15129110.88  | 1.49%             |  |  |  | No            |                  1 | On Loan: No      |
| Lonza Group AG                               | Lonza Group AG                                          | CUSIP: 000000000<br>LEI: 549300EFW4H2TCZ71055 | Long             | EC               | CORP              | CH        |     23258 | NS      | $14920433.77  | 1.47%             |  |  |  | No            |                  2 | On Loan: No      |
| Protagonist Therapeutics Inc                 | Protagonist Therapeutics Inc                            | CUSIP: 74366E102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     68855 | NS      | $7257317.00   | 0.72%             |  |  |  | No            |                  1 | On Loan: No      |
| RadNet Inc                                   | RadNet Inc                                              | CUSIP: 750491102<br>LEI: 529900RECG94V2IZJ970 | Long             | EC               | CORP              | US        |     46906 | NS      | $2621576.34   | 0.26%             |  |  |  | No            |                  1 | On Loan: —       |
| REGENXBIO Inc                                | REGENXBIO Inc                                           | CUSIP: 75901B107<br>LEI: 549300EOES47LATSET33 | Long             | EC               | CORP              | US        |     81282 | NS      | $681143.16    | 0.07%             |  |  |  | No            |                  1 | On Loan: No      |
| Revolution Medicines Inc                     | Revolution Medicines Inc                                | CUSIP: 76155X100<br>LEI: 549300JU3X0LBCQ65892 | Long             | EC               | CORP              | US        |     46968 | NS      | $4567638.00   | 0.45%             |  |  |  | No            |                  1 | On Loan: No      |
| Rhythm Pharmaceuticals Inc                   | Rhythm Pharmaceuticals Inc                              | CUSIP: 76243J105<br>LEI: 529900JPNWXQ8DPLA551 | Long             | EC               | CORP              | US        |    111452 | NS      | $9692980.44   | 0.96%             |  |  |  | No            |                  1 | On Loan: No      |
| Sagimet Biosciences Inc                      | Sagimet Biosciences Inc                                 | CUSIP: 786700104<br>LEI: 2549002OT2F8BV0VPD02 | Long             | EC               | CORP              | US        |    220227 | NS      | $1150686.08   | 0.11%             |  |  |  | No            |                  1 | On Loan: —       |
| Scholar Rock Holding Corp                    | Scholar Rock Holding Corp                               | CUSIP: 80706P103<br>LEI: 549300Z1FLPGL4OWJ459 | Long             | EC               | CORP              | US        |     30077 | NS      | $1478585.32   | 0.15%             |  |  |  | No            |                  1 | On Loan: No      |
| Stoke Therapeutics Inc                       | Stoke Therapeutics Inc                                  | CUSIP: 86150R107<br>LEI: 549300RD25SS2DIJHJ67 | Long             | EC               | CORP              | US        |    132656 | NS      | $4319279.36   | 0.43%             |  |  |  | No            |                  1 | On Loan: No      |
| Summit Therapeutics Inc                      | Summit Therapeutics Inc                                 | CUSIP: 86627T108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    116250 | NS      | $2204100.00   | 0.22%             |  |  |  | No            |                  1 | On Loan: —       |
| Syndax Pharmaceuticals Inc                   | Syndax Pharmaceuticals Inc                              | CUSIP: 87164F105<br>LEI: 529900OF94TRHKZVBS87 | Long             | EC               | CORP              | US        |     24320 | NS      | $568115.20    | 0.06%             |  |  |  | No            |                  1 | On Loan: No      |
| Tempus AI Inc                                | Tempus AI Inc                                           | CUSIP: 88023B103<br>LEI: 2549009LA0KWRAGQBX50 | Long             | EC               | CORP              | US        |     77823 | NS      | $3519156.06   | 0.35%             |  |  |  | No            |                  1 | On Loan: —       |
| Terns Pharmaceuticals Inc                    | Terns Pharmaceuticals Inc                               | CUSIP: 880881107<br>LEI: 254900S1ZDQMF4MYP709 | Long             | EC               | CORP              | US        |    155371 | NS      | $8191159.12   | 0.81%             |  |  |  | No            |                  1 | On Loan: —       |
| Teva Pharmaceutical Industries Ltd           | Teva Pharmaceutical Industries Ltd                      | CUSIP: 881624209<br>LEI: 549300BAFGM4RC74ZJ94 | Long             | EC               | CORP              | IL        |    212205 | NS      | $6391614.60   | 0.63%             |  |  |  | No            |                  1 | On Loan: No      |
| Thermo Fisher Scientific Inc                 | Thermo Fisher Scientific Inc                            | CUSIP: 883556102<br>LEI: HCHV7422L5HDJZCRFL38 | Long             | EC               | CORP              | US        |      9062 | NS      | $4454244.86   | 0.44%             |  |  |  | No            |                  1 | On Loan: No      |
| TScan Therapeutics Inc                       | TScan Therapeutics Inc                                  | CUSIP: 89854M101<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    407010 | NS      | $411080.10    | 0.04%             |  |  |  | No            |                  1 | On Loan: No      |
| ADARX PHARMACEUTICALS INC                    | ADARX PHARMACEUTICALS INC                               | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    860577 | NS      | $11282164.47  | 1.11%             |  |  |  | Yes           |                  3 | On Loan: No      |
| ABCURO SERIES B                              | ABCURO SERIES B                                         | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | GB        |   1092954 | NS      | $1136672.16   | 0.11%             |  |  |  | No            |                  3 | On Loan: No      |
| GENESIS THERAPEUTICS INC                     | GENESIS THERAPEUTICS INC                                | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1370506 | NS      | $7496667.82   | 0.74%             |  |  |  | Yes           |                  3 | On Loan: No      |
| KARTOS THERAPEUTICS INC                      | KARTOS THERAPEUTICS INC                                 | CUSIP: 000000000<br>LEI: N/A                  | Long             | STIV             | CORP              | US        |   1333783 | NS      | $7575887.44   | 0.75%             |  |  |  | Yes           |                  3 | On Loan: No      |
| United Therapeutics Corp                     | United Therapeutics Corp                                | CUSIP: 91307C102<br>LEI: 5299005C4HZL4UWROC14 | Long             | EC               | CORP              | US        |      3080 | NS      | $1826378.40   | 0.18%             |  |  |  | No            |                  1 | On Loan: No      |
| Upstream Bio Inc                             | Upstream Bio Inc                                        | CUSIP: 91678A107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     56530 | NS      | $508770.00    | 0.05%             |  |  |  | No            |                  1 | On Loan: No      |
| Vertex Pharmaceuticals Inc                   | Vertex Pharmaceuticals Inc                              | CUSIP: 92532F100<br>LEI: 54930015RAQRRZ5ZGJ91 | Long             | EC               | CORP              | US        |     20900 | NS      | $9332686.00   | 0.92%             |  |  |  | No            |                  1 | On Loan: No      |
| Viking Therapeutics Inc                      | Viking Therapeutics Inc                                 | CUSIP: 92686J106<br>LEI: 529900IVC72YPFA25M37 | Long             | EC               | CORP              | US        |     56322 | NS      | $1832717.88   | 0.18%             |  |  |  | No            |                  1 | On Loan: No      |
| CONTRA VIGIL NEUROSCIE                       | CONTRA VIGIL NEUROSCIE                                  | CUSIP: 926CVR010<br>LEI: N/A                  | Long             |  | CORP              | US        |    131344 | NS      | $6567.20      | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| Viridian Therapeutics Inc                    | Viridian Therapeutics Inc                               | CUSIP: 92790C104<br>LEI: 549300C775BNYF550E70 | Long             | EC               | CORP              | US        |    173120 | NS      | $3386227.20   | 0.33%             |  |  |  | No            |                  1 | On Loan: No      |
| Vor BioPharma Inc                            | Vor BioPharma Inc                                       | CUSIP: 929033207<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     43710 | NS      | $779786.40    | 0.08%             |  |  |  | No            |                  1 | On Loan: No      |
| Voyager Therapeutics Inc                     | Voyager Therapeutics Inc                                | CUSIP: 92915B106<br>LEI: 54930082S4XVR0ZWCC74 | Long             | EC               | CORP              | US        |    141787 | NS      | $547297.82    | 0.05%             |  |  |  | No            |                  1 | On Loan: No      |
| BlackRock Liquidity Funds                    | BlackRock Liquidity Funds: T-Fund, Institutional Shares | CUSIP: 09248U718<br>LEI: 5493007YVNX55LTRQ706 | Long             | STIV             | RF                | US        |  48671382 | NS      | $48671381.57  | 4.81%             |  |  |  | No            |                  1 | On Loan: No      |
| GOLDFINCH BIO INC                            | GOLDFINCH BIO INC                                       | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   3409215 | NS      | $1022764.50   | 0.10%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Waters Corp                                  | Waters Corp                                             | CUSIP: 941848103<br>LEI: 5T547R1474YC9HOD8Q74 | Long             | EC               | CORP              | US        |     14015 | NS      | $4173667.00   | 0.41%             |  |  |  | No            |                  1 | On Loan: No      |
| Immunocore Limited                           | Immunocore Limited                                      | CUSIP: 000000000<br>LEI: N/A                  | Long             | STIV             | CORP              | US        |    321900 | NS      | $9705285.00   | 0.96%             |  |  |  | No            |                  2 | On Loan: No      |
| CELLARITY INC                                | CELLARITY INC                                           | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   2430833 | NS      | $5931232.52   | 0.59%             |  |  |  | Yes           |                  3 | On Loan: No      |
| INSITRO INC                                  | INSITRO INC                                             | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    196818 | NS      | $1645398.48   | 0.16%             |  |  |  | Yes           |                  3 | On Loan: No      |
| NUMAB THERAPEUTICS AG                        | NUMAB THERAPEUTICS AG                                   | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | CH        |   1139305 | NS      | $8107360.49   | 0.80%             |  |  |  | Yes           |                  3 | On Loan: No      |
| BRIGHT PEAK THERAPEUTICS INC                 | BRIGHT PEAK THERAPEUTICS INC                            | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   3191830 | NS      | $2393872.50   | 0.24%             |  |  |  | Yes           |                  3 | On Loan: No      |
| NIKANG THERAPEUTICS INC                      | NIKANG THERAPEUTICS INC                                 | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1394189 | NS      | $5339743.87   | 0.53%             |  |  |  | Yes           |                  3 | On Loan: No      |
| PsiQuantum Corp                              | PsiQuantum Corp                                         | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    571947 | NS      | $23650008.45  | 2.34%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Quanta Dialysis Technologies Ltd             | Quanta Dialysis Technologies Ltd                        | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | GB        | 115766240 | NS      | $5516216.94   | 0.54%             |  |  |  | Yes           |                  3 | On Loan: No      |
| NUCLEIX LTD                                  | NUCLEIX LTD                                             | CUSIP: 000000000<br>LEI: N/A                  | Long             | EP               | CORP              | US        |   2379480 | NS      | $1570456.80   | 0.16%             |  |  |  | Yes           |                  3 | On Loan: No      |
| LARONDE INC                                  | LARONDE INC                                             | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    482077 | NS      | $9313727.64   | 0.92%             |  |  |  | Yes           |                  3 | On Loan: No      |
| SWIFT HEALTH SYSTEMS INC                     | SWIFT HEALTH SYSTEMS INC                                | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      2078 | NS      | $4634.03      | 0.00%             |  |  |  | Yes           |                  3 | On Loan: No      |
| MIRVIE INC                                   | MIRVIE INC                                              | CUSIP: 000000000<br>LEI: N/A                  | Long             | EP               | CORP              | US        |   2793833 | NS      | $4134872.84   | 0.41%             |  |  |  | Yes           |                  3 | On Loan: No      |
| AMUNIX INC                                   | AMUNIX INC                                              | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   5657068 | NS      | $169712.04    | 0.02%             |  |  |  | Yes           |                  3 | On Loan: No      |
| AFFINIVAX INC                                | AFFINIVAX INC                                           | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    183164 | NS      | $672211.88    | 0.07%             |  |  |  | Yes           |                  3 | On Loan: No      |
| NUCLEIX LTD                                  | NUCLEIX LTD                                             | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |      1300 | NS      | $1030276.00   | 0.10%             |  |  |  | Yes           |                  3 | On Loan: No      |
| RENAGADE THERAPEUTICS A 2                    | RENAGADE THERAPEUTICS A 2                               | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   3584906 | NS      | $13049057.84  | 1.29%             |  |  |  | No            |                  3 | On Loan: No      |
| EXO IMAGING INC                              | EXO IMAGING INC                                         | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   1053928 | NS      | $779906.73    | 0.08%             |  |  |  | Yes           |                  3 | On Loan: No      |
| EXO IMAGING INC                              | EXO IMAGING INC                                         | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     22576 | NS      | $8353.11      | 0.00%             |  |  |  | Yes           |                  3 | On Loan: No      |
| ABCURO SERIES C EQUITY                       | ABCURO SERIES C EQUITY                                  | CUSIP: 000000000<br>LEI: N/A                  | Long             | STIV             | CORP              | US        |    241900 | NS      | $933734.00    | 0.09%             |  |  |  | No            |                  3 | On Loan: No      |
| KARTOS THERAPEUTICS INC                      | KARTOS THERAPEUTICS INC                                 | CUSIP: 000000000<br>LEI: N/A                  | Long             | STIV             | CORP              | US        |    366962 | NS      | $2084344.16   | 0.21%             |  |  |  | Yes           |                  3 | On Loan: No      |
| BlackRock Funds III                          | BlackRock Cash Funds: Institutional, SL Agency Shares   | CUSIP: 066922519<br>LEI: 5493008LW2651I1QB503 | Long             | STIV             | RF                | US        |  11103934 | NS      | $11106155.22  | 1.10%             |  |  |  | No            |                  1 | On Loan: No      |
| INSITRO INC                                  | INSITRO INC                                             | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    802478 | NS      | $6708716.08   | 0.66%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Wuxi Biologics Cayman Inc                    | Wuxi Biologics Cayman Inc                               | CUSIP: 000000000<br>LEI: 5493001TD2TH6VDTJU11 | Long             | EC               | CORP              | KY        |   1152500 | NS      | $4956316.46   | 0.49%             |  |  |  | No            |                  2 | On Loan: No      |
| EVERLY WELL INC                              | EVERLY WELL INC                                         | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    382775 | NS      | $5022008.00   | 0.50%             |  |  |  | Yes           |                  3 | On Loan: No      |
| MIRVIE SERIES C                              | MIRVIE SERIES C                                         | CUSIP: 000000000<br>LEI: N/A                  | Long             | STIV             | CORP              | US        |    724806 | NS      | $1630813.50   | 0.16%             |  |  |  | No            |                  3 | On Loan: No      |
| KAILERA THERAPEUTICS INC                     | KAILERA THERAPEUTICS INC                                | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    250286 | NS      | $3504004.00   | 0.35%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Angitia Biopharmaceuticals Limited           | Angitia Biopharmaceuticals Limited                      | CUSIP: 000000000<br>LEI: N/A                  | Long             | STIV             | CORP              | US        |    296024 | NS      | $2927677.36   | 0.29%             |  |  |  | Yes           |                  3 | On Loan: No      |
| GOLDFINCH EQUITY WARRANTS                    | GOLDFINCH EQUITY WARRANTS                               | CUSIP: 000000000<br>LEI: N/A                  | N/A              | DE               |  | US        |    441503 | NS      | $4.42         | 0.00%             |  |  |  | No            |                  3 | On Loan: No      |
| KARTOS THERAPEUTICS INC                      | KARTOS THERAPEUTICS INC                                 | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    531322 | NS      | $533765.71    | 0.05%             |  |  |  | Yes           |                  3 | On Loan: No      |
| Galderma Group AG                            | Galderma Group AG                                       | CUSIP: 000000000<br>LEI: 89450001OK6O8ELQ4584 | Long             | EC               | CORP              | CH        |     29482 | NS      | $5794205.90   | 0.57%             |  |  |  | No            |                  2 | On Loan: No      |
| Roche Holding AG                             | Roche Holding AG                                        | CUSIP: 000000000<br>LEI: 549300U41AUUVOAAOB37 | Long             | EC               | CORP              | CH        |     42839 | NS      | $17096652.61  | 1.69%             |  |  |  | No            |                  2 | On Loan: No      |
| Daiichi Sankyo Co Ltd                        | Daiichi Sankyo Co Ltd                                   | CUSIP: 000000000<br>LEI: 353800XGIU2IHQGC9504 | Long             | EC               | CORP              | JP        |     93900 | NS      | $1679933.29   | 0.17%             |  |  |  | No            |                  2 | On Loan: No      |
| Zealand Pharma A/S                           | Zealand Pharma A/S                                      | CUSIP: 000000000<br>LEI: 549300ITBB1ULBL4CZ12 | Long             | EC               | CORP              | DK        |     46920 | NS      | $2185064.48   | 0.22%             |  |  |  | No            |                  2 | On Loan: No      |
| Nyxoah SA                                    | Nyxoah SA                                               | CUSIP: 000000000<br>LEI: 5493002O1ESKZ18OXR80 | Long             | EC               | CORP              | BE        |    112019 | NS      | $327095.48    | 0.03%             |  |  |  | No            |                  1 | On Loan: —       |
| Akeso Inc                                    | Akeso Inc                                               | CUSIP: 000000000<br>LEI: 254900ECWYGR3QW5GF30 | Long             | EC               | CORP              | KY        |    204000 | NS      | $3473488.84   | 0.34%             |  |  |  | No            |                  2 | On Loan: No      |
| GSK PLC                                      | GSK PLC                                                 | CUSIP: 000000000<br>LEI: 5493000HZTVUYLO1D793 | Long             | EC               | CORP              | GB        |    521765 | NS      | $14372267.16  | 1.42%             |  |  |  | No            |                  2 | On Loan: No      |
| AstraZeneca PLC                              | AstraZeneca PLC                                         | CUSIP: 000000000<br>LEI: PY6ZZQWO2IZFZC3IOL08 | Long             | EC               | CORP              | GB        |     57869 | NS      | $11412924.18  | 1.13%             |  |  |  | No            |                  1 | On Loan: No      |
| Biohaven Ltd                                 | Biohaven Ltd                                            | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | VG        |     46808 | NS      | $395995.68    | 0.04%             |  |  |  | No            |                  1 | On Loan: No      |
| Kiniksa Pharmaceuticals International Plc    | Kiniksa Pharmaceuticals International Plc               | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | GB        |     64037 | NS      | $3083381.55   | 0.30%             |  |  |  | No            |                  1 | On Loan: No      |
| Medtronic PLC                                | Medtronic PLC                                           | CUSIP: 000000000<br>LEI: 549300GX3ZBSQWUXY261 | Long             | EC               | CORP              | IE        |    115270 | NS      | $9988145.50   | 0.99%             |  |  |  | No            |                  1 | On Loan: No      |
| Novocure Ltd                                 | Novocure Ltd                                            | CUSIP: 000000000<br>LEI: 213800YPP55UMHWA4826 | Long             | EC               | CORP              | JE        |    210016 | NS      | $2289174.40   | 0.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Roivant Sciences Ltd                         | Roivant Sciences Ltd                                    | CUSIP: 000000000<br>LEI: 549300DL466NY5J6U724 | Long             | EC               | CORP              | BM        |    240456 | NS      | $6660631.20   | 0.66%             |  |  |  | No            |                  1 | On Loan: No      |
| QIAGEN NV                                    | QIAGEN NV                                               | CUSIP: 000000000<br>LEI: 54930036WK3GMCN17Z57 | Long             | EC               | CORP              | NL        |     85732 | NS      | $3432709.28   | 0.34%             |  |  |  | No            |                  1 | On Loan: No      |
| WaVe Life Sciences Ltd                       | WaVe Life Sciences Ltd                                  | CUSIP: 000000000<br>LEI: 54930070006GPKFYZ813 | Long             | EC               | CORP              | SG        |     96283 | NS      | $698051.75    | 0.07%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2026-04-30

**Name of Applicant:** BlackRock Health Sciences Term Trust

**Signature:** Chuck Pulsfort

**Name of Signer:** Chuck Pulsfort

**Title:** Assistant Treasurer